Table 3 Safety outcomes and arrythmia within the 7 days in patients assigned to dexmedetomidine and placebo group
Total (n = 331) | Dexmedetomidine group (n = 165) | Placebo group (n = 166) | P | |
|---|---|---|---|---|
Hypotension | ||||
Yes | 13 (3.9) | 12 (7.3) | 1 (0.6) | < 0.01 |
No | 318 (96.1) | 153 (92.7) | 165 (99.4) | |
Bradycardia | ||||
Yes | 7 (2.1) | 6 (3.6) | 1 (0.6) | 0.07 |
No | 324 (97.9) | 159 (96.4) | 165 (99.4) | |
Ventricular arrythmia | ||||
Yes | 21 (6.3) | 8 (4.8) | 13 (7.8) | 0.27 |
No | 310 (93.7 | 157 (95.2 | 153 (92.2) | |
Supra ventricular arrythmia | ||||
Yes | 139 (42) | 74 (44.8) | 65 (39.2) | 0.29 |
No | 192 (58) | 91 (55.2) | 101 (60.8) | |